StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)

Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –

Zevra Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Zevra Therapeutics's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $61.93M, up 4.1% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$61.93M+4.1%
FY2024Dec 31, 2024$59.50M+1074.6%
FY2023Dec 31, 2023$5.07M–
FY2022Dec 31, 2022$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$61.93M+4.1%
Q3 FY2025Sep 30, 2025$61.31M+4.1%
Q2 FY2025Jun 30, 2025$60.69M+4.1%
Q1 FY2025Mar 31, 2025$60.09M+1087.8%
Q4 FY2024Dec 31, 2024$59.50M+1074.6%
Q3 FY2024Sep 30, 2024$58.90M+1061.1%
Q2 FY2024Jun 30, 2024$58.33M–
Q1 FY2024Mar 31, 2024$5.06M+547.8%
Q4 FY2023Dec 31, 2023$5.07M+548.7%
Q3 FY2023Sep 30, 2023$5.07M–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2020Sep 30, 2020$781.00K–
Q2 FY2020Jun 30, 2020$781.00K–

More Zevra Therapeutics figures

See a number that looks wrong?